Abstract
Frontotemporal Lobar Degeneration (FTLD) is characterized by behavioral changes, executive dysfunctions, and language impairment, sustained by different neuropathological patterns. The collective efforts of clinical, pathological and genetic studies have recently opened new insights into the underpinnings of pathological mechanisms of this complex disorder. Different types of inclusions define the new conceptual framework for FTLD classification. Up to now, Tau (FTLDTau-positive), TAR DNA-binding protein (TDP43, FTLD Tau-negative TDP43-positive) have been recognized as the most frequent neuropathological hallmarks of FTLD. In some clinical cases, monogenic forms are identified, mainly due to Microtubule Associated Protein (MAPT) or Granulin (GRN) mutations.
No treatments for FTLD are available yet, and off-label medications studies testing potential modifying treatments on the basis of neuropathological positive, inhibitors of Tau kinases or manipulation of Tau-processing haploinsuffciency associated with GRN mutations, has been counteracted into pathological processing of TDP-43 and other key-molecules involved and their consequent translocation from nucleus to cytoplasm, and growing number of potential therapeutic targets. In this continuously new findings on molecular targets and modifying therapies in FTLD.
Keywords: Frontotemporal Lobar Degeneration, Frontotemporal Dementia, treatment, therapies, Tau, Progranulin, Microtubule Associated Protein (MAPT), Granulin (GRN) mutations, haploinsuffciency, RNA-binding proteins
Current Medicinal Chemistry
Title: Disease-Modifying Therapies in Frontotemporal Lobar Degeneration
Volume: 19 Issue: 7
Author(s): B. Bigni, E. Premi, A. Pilotto, A. Padovani and B. Borroni
Affiliation:
Keywords: Frontotemporal Lobar Degeneration, Frontotemporal Dementia, treatment, therapies, Tau, Progranulin, Microtubule Associated Protein (MAPT), Granulin (GRN) mutations, haploinsuffciency, RNA-binding proteins
Abstract: Frontotemporal Lobar Degeneration (FTLD) is characterized by behavioral changes, executive dysfunctions, and language impairment, sustained by different neuropathological patterns. The collective efforts of clinical, pathological and genetic studies have recently opened new insights into the underpinnings of pathological mechanisms of this complex disorder. Different types of inclusions define the new conceptual framework for FTLD classification. Up to now, Tau (FTLDTau-positive), TAR DNA-binding protein (TDP43, FTLD Tau-negative TDP43-positive) have been recognized as the most frequent neuropathological hallmarks of FTLD. In some clinical cases, monogenic forms are identified, mainly due to Microtubule Associated Protein (MAPT) or Granulin (GRN) mutations.
No treatments for FTLD are available yet, and off-label medications studies testing potential modifying treatments on the basis of neuropathological positive, inhibitors of Tau kinases or manipulation of Tau-processing haploinsuffciency associated with GRN mutations, has been counteracted into pathological processing of TDP-43 and other key-molecules involved and their consequent translocation from nucleus to cytoplasm, and growing number of potential therapeutic targets. In this continuously new findings on molecular targets and modifying therapies in FTLD.
Export Options
About this article
Cite this article as:
Bigni B., Premi E., Pilotto A., Padovani A. and Borroni B., Disease-Modifying Therapies in Frontotemporal Lobar Degeneration, Current Medicinal Chemistry 2012; 19 (7) . https://dx.doi.org/10.2174/092986712799320637
DOI https://dx.doi.org/10.2174/092986712799320637 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
G Protein - Mediated Signaling: Same Receptor, Multiple Effectors
Current Molecular Pharmacology Regulation of Cell Death and Survival by Resveratrol: Implications for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Targeting Drug-Resistant Prostate Cancer with Dual PI3K/mTOR Inhibition
Current Medicinal Chemistry T Cell Redirecting Therapies for Cancer Treatment
Current Cancer Drug Targets Modulation of intracellular pH in human ovarian cancer.
Current Molecular Medicine Multidrug Resistance Protein 4 (MRP4/ABCC4): A Suspected Efflux Transporter for Human’s Platelet Activation
Protein & Peptide Letters Regulation and Quantification of Cellular Mitochondrial Morphology and Content
Current Pharmaceutical Design CB1 Cannabinoid Receptors and their Associated Proteins
Current Medicinal Chemistry Tumor-Derived Extracellular Fragments of Receptor Protein Tyrosine Phosphatases (RPTPs) as Cancer Molecular Diagnostic Tools
Anti-Cancer Agents in Medicinal Chemistry Addictions and Stress: Clues for Cocaine Pharmacotherapies
Current Pharmaceutical Design New Insights about the Potential Application of the Association of Vitamins C (Sodium Ascorbate) and K3 (Menadione) as Auxiliary Therapy in Cancer Treatment
Medicinal Chemistry Reviews - Online (Discontinued) Approaches to Target Profiling of Natural Products
Current Medicinal Chemistry Anti-Inflammatory Therapy for Alzheimer’s Disease from Epidemiological Fact to New Mechanisms of Action
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Thyroid Hormone Modulation of Immunity: Its Participation in Chronic Stress-Induced Immune Alterations
Current Immunology Reviews (Discontinued) Angiogenesis and Metastasis Inhibitors for the Treatment of Malignant Melanoma
Mini-Reviews in Medicinal Chemistry Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets
Current Drug Targets An Overview of Published Papers and Important Developments in the Past Three Years
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeted Therapies in Lung Cancers: Current Landscape and Future Prospects
Recent Patents on Anti-Cancer Drug Discovery Recent Advancements in 1,4-Disubstituted 1H-1,2,3-Triazoles as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Inhibition of Rho/Rho-Kinase as Therapeutic Strategy to Promote CNS Axonal Regeneration
Central Nervous System Agents in Medicinal Chemistry